Technology
|
Intellectual Property
|
Pipeline & Partners
|
Corporate
- Overview
- Management
- Board
- Investigators
- Policies
|
Investors
|
News
|
Resources

Stock Information

Prices delayed by at least 20 minutes. Retrieving this share price indicates your acceptance of thsee terms.

“Present shRNA expression systems provide good target knockdown and have not generally resulted in unexpected toxicities.”

Snove & Rossi
Nature Methods 2006
Read the paper

Technology

Unique Platform
Treatment & Cure
What is RNAi?
siRNA vs shRNA
Bibliography
Glossary

Intellectual Property

ddRNAi Patent
Patent Estate
IP Actions

Pipeline & Partners

Pipeline Summary
In-house Programs
Out-licensed Programs
Licensing
Partners

Corporate

Overview
Management
Board
Investigators
Policies

Investors

Investor Info
2012 AGM
Annual Reports
ASX Stock Info
Governance

News

Media Releases
ASX Releases
Archived
Events

Benitec Biopharma Ltd, 1-15 Barr St Balmain (Sydney) NSW Australia P.+ 61 (0) 2 9555 6986 E. info@benitec.com